SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000891293-22-000032
Filing Date
2022-06-16
Accepted
2022-06-16 16:19:11
Documents
1
Period of Report
2022-06-14

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 7056
  Complete submission text file 0000891293-22-000032.txt   8540
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Issuer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address C/O CTI BIOPHARMA CORP. 3101 WESTERN AVE., SUITE 600 SEATTLE WA 98121
Business Address
KIRSKE DAVID (Reporting) CIK: 0001276750 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-28386 | Film No.: 221020817